Jefferies Maintains NxStage Medical to Buy with Price Target $27.00

Brokerage firm Jefferies Maintains its rating on NxStage Medical(NASDAQ:NXTM). In a research note issued to the investors, the brokerage major Raises the price-target to $27.00 per share. The shares have been rated Buy. The rating by Jefferies was issued on Aug 5, 2016.

In a different note, On Aug 2, 2016, Canaccord Genuity said it Maintains its rating on NxStage Medical. In the research note, the firm Raises the price-target to $22.00 per share. The shares have been rated ‘Buy’ by the firm.

NxStage Medical (NXTM) shares turned negative on Wednesdays trading session with the shares closing down -0.45 points or -1.84% at a volume of 7,49,474. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $24.77. The peak price level was also seen at $24.77 while the days lowest was $23.825. Finally the shares closed at $24. The 52-week high of the shares is $26.07 while the 52-week low is $13.49. According to the latest information available, the market cap of the company is $1,549 M.

NxStage Medical(NXTM) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $92.21M. Analysts had an estimated revenue of $89.44M. Earnings per share were $-0.03. Analysts had estimated an EPS of $-0.04.

Several Insider Transactions has been reported to the SEC. On May 12, 2016, Joseph E Jr Turk (President) sold 1,500 shares at $17.89 per share price.Also, On Apr 15, 2016, Jeffrey H Burbank (Chief Executive Officer) sold 10,000 shares at $16.21 per share price.On Apr 15, 2016, Winifred L Swan (SVP and General Counsel) sold 6,260 shares at $16.56 per share price, according to the Form-4 filing with the securities and exchange commission.

NxStage Medical Inc. is a medical device company. The Company is engaged in the development manufacturing and marketing of products for the treatment of kidney failure fluid overload and related blood treatments and procedures. The Company’s products include the System One Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles. Its primary product the System One is a small portable easy-to-use hemodialysis system. It is designed to deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller portable easy-to-use form that can be used by healthcare professionals and trained lay users alike in a variety of settings including patient homes as well as more traditional care settings such as hospitals and dialysis centers. The Company operates in three reportable business segments: System One In-Center and Services.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

NxStage Medical - Is it time to Sell?

Top Brokerage Firms are advising their investors on NxStage Medical. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.